MYOS RENS TECHNOLOGY INC. (NASDAQ:MYOS) Files An 8-K Regulation FD Disclosure

MYOS RENS TECHNOLOGY INC. (NASDAQ:MYOS) Files An 8-K Regulation FD Disclosure
Item 7.01

Regulation FD Disclosure.
Story continues below

On January 30, 2019, MYOS RENS Technology Inc. (the “Company”) received net proceeds of approximately $1.1 million from the sale of its tax benefits through the New Jersey Technology Business Tax Certificate Transfer Program. This program provides a mechanism for approved New Jersey technology and biotechnology companies to sell their unused net operating loss carryovers for cash. The Company expects to use the proceeds from the sale for general working capital.

In accordance with General Instruction B.2 of Form 8-K, the foregoing information shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall such information, including Exhibit 99.1, be deemed incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

About MYOS RENS TECHNOLOGY INC. (NASDAQ:MYOS)

MYOS RENS Technology Inc. (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity. The Company is focused on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining the health and performance of muscle tissue. MYOS is evaluating the modulation of myostatin. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement.

An ad to help with our costs